Drug: Lyrica
Company: Pfizer
Total spend Q1, 2012: $25.1 million
Total spend Q1, 2011: $30.8 million
Watch the TV commercial here >>

While Pfizer is remaking itself in a world without Lipitor exclusivity, it will at least be able to carry forward with protection another 5 years on its super blockbuster drug Lyrica. A federal judge in July upheld its patents for Lyrica, the pain drug and epilepsy treatment. Released in 2004, the drug first topped the $1 billion sales milestone in 2008 and its sales have just kept growing. Last year, Lyrica generated $3.7 billion in revenue. Federal authorities did say that some of that success was attributable to misbehavior. Lyrica was one of the drugs included in Pfizer's $2.3 billion marketing settlement in 2009. But that is past and the drug keeps generating big sales, including $458 million in the first quarter, says, which translates as a 6% jump.


Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.